Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18708606 | LIQUID DRESSING FOR PROMOTING WOUND HEALING | May 2024 | April 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18640949 | MICRONIZED EGGSHELL MEMBRANE PARTICLES AND THE USE THEREOF TO PROMOTE THE HEALING OF WOUNDS | April 2024 | April 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18613281 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE | March 2024 | July 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18441957 | ENTERIC TABLET CONTAINING DIMETHYL FUMARATE | February 2024 | May 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18489631 | TOPICAL DRUG DELIVERY DEVICES AND METHODS OF USE | October 2023 | June 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18472258 | KAOLIN-BASED HEMOSTATIC GAUZE AND PREPARATION METHOD THEREOF | September 2023 | March 2025 | Abandon | 18 | 2 | 0 | No | No |
| 18345279 | GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS | June 2023 | September 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18341748 | COMPOSITE MATERIAL FOR RAPID BLOOD CLOTTING AND PREPARATION METHOD THEREOF | June 2023 | April 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18116964 | REINFORCED POROUS COLLAGEN SHEET | March 2023 | January 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18172042 | INJECTABLE GELS COMPRISING CROSS-LINKED HYALURONIC ACID AND HYDROXYAPATITE, AND METHODS OF MANUFACTURING THEREOF | February 2023 | March 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18092761 | METHOD OF MAKING TRANSDERMAL AMPHETAMINE COMPOSITION WITH LOW LEVELS OF CARBAMATE | January 2023 | June 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 18080433 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | December 2022 | April 2025 | Abandon | 28 | 2 | 0 | Yes | No |
| 18062736 | WOUND CARE COVERING | December 2022 | September 2024 | Abandon | 21 | 2 | 1 | No | No |
| 17943538 | SWELLABLE POLYMERIC MATERIALS AND USEFUL ARTICLES INCORPORATING SAME | September 2022 | August 2024 | Abandon | 23 | 2 | 1 | No | No |
| 17835193 | Method for Adjusting the Release of Active Agent in a Transdermal Delivery System | June 2022 | April 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17721853 | HOMEOSTATIC SINGLE LAYER DRESSING | April 2022 | May 2024 | Abandon | 25 | 6 | 0 | Yes | No |
| 17685818 | Transdermal Delivery System | March 2022 | November 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17682808 | ANHYDROUS HYDROCOLLOID MATRIX COMPRISING HOMOGENEOUSLY DISTRIBUTED ENCAPSULATED THERAPEUTIC AGENTS | February 2022 | April 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 17681064 | NON-CULTURED, PARTIALLY DIGESTED, CRYOPRESERVED CARTILAGE PRODUCT | February 2022 | February 2025 | Allow | 36 | 2 | 1 | Yes | No |
| 17589262 | Multi-Day Patch for the Transdermal Administration of Rotigotine | January 2022 | May 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17569862 | TRANSDERMAL AMPHETAMINE COMPOSITIONS WITH LOW LEVELS OF CARBAMATE | January 2022 | November 2022 | Allow | 10 | 1 | 1 | Yes | No |
| 17541491 | TRANSDERMAL DEVICE COMPRISING NSAID OR ANALGESIC PRODRUG MOLECULES | December 2021 | May 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17536986 | THIOL AND DISULFIDE-CONTAINING AGENTS FOR INCREASING MEIBOMIAN GLAND LIPID SECRETION | November 2021 | September 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17523661 | PHARMACEUTICAL COMPOSITIONS | November 2021 | August 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17523814 | Sublingual Delivery for Mitigation of Side Effects Associated with Sildenafil Citrate | November 2021 | March 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17505798 | MICROCELL SYSTEMS FOR DELIVERING BENEFIT AGENTS | October 2021 | December 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17603885 | TRANSDERMAL THERAPEUTIC SYSTEM | October 2021 | June 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17482871 | Composition for the Transdermal Delivery of Fentanyl | September 2021 | November 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17441256 | ENTERIC TABLET CONTAINING DIMETHYL FUMARATE | September 2021 | February 2024 | Abandon | 29 | 4 | 0 | Yes | No |
| 17440097 | HERBICIDAL COMPOSITION AND METHOD FOR CONTROLLING WEEDS | September 2021 | May 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17471330 | SOLID FORMULATION | September 2021 | November 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17464616 | SUBLINGUAL DELIVERY FOR MITIGATION OF SIDE EFFECTS ASSOCIATED WITH TRAZODONE | September 2021 | December 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17407982 | LIQUID HEMOSTATIC MEDICAL MATERIAL | August 2021 | January 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17359120 | OPHTHALMIC COMPOSITIONS | June 2021 | October 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17417703 | COMPOSITIONS AND METHODS FOR TREATING BURNS, WOUNDS, AND SKIN DISORDERS | June 2021 | June 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17347256 | AMMONIA PAD WITH RELEASABLE SEAL | June 2021 | March 2025 | Allow | 45 | 3 | 1 | Yes | No |
| 17311379 | COMPOSITION COMPRISING CHICORY ROOT AND PEA CELL WALL FIBER FOR TREATING BRACHYSPIRA INFECTIONS | June 2021 | February 2025 | Allow | 44 | 1 | 2 | Yes | No |
| 17337691 | COMPOSITIONS FOR CONTROLLING PHYTOPLANKTON CONTAMINATION | June 2021 | February 2024 | Allow | 32 | 2 | 0 | Yes | No |
| 17298745 | COMPOSITION COMPRISING ELECAMPANE EXTRACT FOR ALLEVIATING PREMENSTRUAL SYNDROME SYMPTOM | June 2021 | September 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17290780 | MEDICINE FOR TREATMENT OF PSORIASIS AND PRODUCTION METHOD THEREOF | May 2021 | October 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17279977 | EXTERNAL PREPARATION | March 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17196599 | METHODS OF TREATING UREA CYCLE DISORDERS AND MAPLE SYRUP URINE DISEASE | March 2021 | November 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 17196416 | PALATABLE COMPOSITIONS INCLUDING SODIUM PHENYLBUTYRATE AND USES THEREOF | March 2021 | September 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17274416 | TRANSDERMAL PATCHES FOR USE IN AURICULOTHERAPY | March 2021 | August 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17179251 | PREVENTION AND TREATMENT OF INFECTIOUS DISEASE USING LOW CONCENTRATION HYPOCHLOROUS ACID SOLUTIONS | February 2021 | June 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17176203 | TASTE-MASKED PHARMACEUTICAL COMPOSITIONS WITH GASTROSOLUBLE PORE-FORMERS | February 2021 | March 2025 | Abandon | 49 | 3 | 1 | No | No |
| 17172235 | WEARABLE LIPOSOMAL CANNABIDIOL TRANSDERMAL PATCH | February 2021 | September 2023 | Abandon | 31 | 1 | 1 | No | No |
| 17147903 | ANTITOXIC FIBERS AND FIBROUS MEDIA AND METHODS FOR MANUFACTURING SAME | January 2021 | August 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17130415 | STIMULUS-RESPONSIVE MICELLAR CARRIER | December 2020 | November 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 17128293 | TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF | December 2020 | March 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17254104 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF HAEMORRHOIDS | December 2020 | December 2024 | Abandon | 48 | 3 | 1 | No | No |
| 17114890 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE | December 2020 | May 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17101005 | FIBRINOGEN COMPOSITION, METHOD AND WOUND ARTICLES | November 2020 | October 2024 | Abandon | 47 | 2 | 1 | No | No |
| 17056394 | SYNERGISTIC HEPATOPROTECTIVE COMPOSITION | November 2020 | December 2024 | Allow | 49 | 2 | 1 | Yes | No |
| 17054975 | LONG LASTING ANTIMICROBIAL SURFACES BASED ON THE CROSS-LINKING OF NATURAL OILS WITHIN POLYMER NETWORKS | November 2020 | March 2025 | Abandon | 52 | 4 | 1 | Yes | No |
| 17073510 | Dermal Delivery Device | October 2020 | April 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 17069758 | Transdermal Delivery | October 2020 | March 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17069571 | Transdermal Delivery | October 2020 | March 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17062379 | THERAPEUTIC ELASTIC BANDAGE FOR MODULATING THE ENDOCANNABINOID SYSTEM | October 2020 | April 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17035705 | Antibacterial Cellulose Hydrogels and Preparation Method therefor | September 2020 | February 2024 | Abandon | 41 | 2 | 0 | Yes | No |
| 16979577 | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING NICOTINE AND SILICONE ACRYLIC HYBRID POLYMER | September 2020 | February 2023 | Abandon | 29 | 0 | 1 | No | No |
| 16979572 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF BUPRENORPHINE COMPRISING A SILICONE ACRYLIC HYBRID POLYMER | September 2020 | February 2023 | Abandon | 29 | 0 | 1 | No | No |
| 15733596 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING A SILICONE ACRYLIC HYBRID POLYMER | September 2020 | September 2022 | Abandon | 24 | 1 | 1 | No | No |
| 15733595 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING A SILICONE ACRYLIC HYBRID POLYMER | September 2020 | September 2022 | Abandon | 24 | 2 | 1 | Yes | No |
| 17007712 | Sealant Dressing with Protected Reactive Components | August 2020 | April 2025 | Allow | 55 | 5 | 1 | Yes | No |
| 17005901 | TRANSDERMAL DEVICE COMPRISING ACETAMINOPHEN PRODRUG | August 2020 | June 2022 | Allow | 21 | 3 | 1 | Yes | No |
| 16975827 | METHYLPHENIDATE-CONTAINING TRANSDERMAL PATCH | August 2020 | February 2024 | Abandon | 41 | 5 | 0 | No | No |
| 16938234 | DERMAL PATCH FOR TRANSDERMAL ADMINISTRATION OF GHRELIN PATHWAY BLOCKER | July 2020 | November 2023 | Abandon | 40 | 2 | 0 | No | Yes |
| 16933836 | TRANSDERMAL DRUG DELIVERY METHOD AND SYSTEM | July 2020 | November 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16961361 | SUSPENSION COMPOSITIONS OF MULTI-TARGET INHIBITORS | July 2020 | May 2024 | Abandon | 46 | 4 | 1 | Yes | No |
| 16925551 | TOPICAL FORMULATIONS WITH RESINIFERATOXIN NANOPARTICLES AND METHODS | July 2020 | March 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 16913646 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | June 2020 | December 2022 | Abandon | 30 | 3 | 0 | No | No |
| 16955437 | Biomedical Foam | June 2020 | September 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16898120 | TOPICAL COMPOSITIONS | June 2020 | June 2021 | Allow | 13 | 1 | 0 | Yes | No |
| 16898201 | GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS | June 2020 | January 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 16895150 | Napped Coated Wound Dressing | June 2020 | June 2024 | Allow | 48 | 4 | 1 | No | No |
| 16885429 | TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF | May 2020 | February 2021 | Abandon | 8 | 1 | 0 | No | No |
| 16877957 | DEPOT FORMULATIONS | May 2020 | August 2023 | Abandon | 39 | 2 | 1 | No | No |
| 16974343 | Powder for oral suspension containing lamotrigine | May 2020 | November 2023 | Abandon | 42 | 3 | 1 | No | No |
| 15930141 | COMPOSITIONS FOR CONTROLLING PHYTOPLANKTON CONTAMINATION | May 2020 | April 2021 | Allow | 11 | 1 | 1 | Yes | No |
| 16863868 | PAIN RELIEVING SYSTEM | April 2020 | February 2023 | Abandon | 33 | 1 | 1 | No | No |
| 16862469 | PAIN RELIEVER COMPOSITION | April 2020 | May 2024 | Abandon | 49 | 3 | 1 | No | No |
| 16861872 | Composition for the Transdermal Delivery of Fentanyl | April 2020 | October 2021 | Abandon | 17 | 2 | 0 | No | No |
| 16759935 | Extended Wear-Time Dressing | April 2020 | June 2023 | Allow | 38 | 2 | 1 | Yes | No |
| 16859443 | DEPOT FORMULATIONS | April 2020 | January 2023 | Abandon | 32 | 3 | 0 | Yes | No |
| 16857304 | APIXABAN TRANSDERMAL DELIVERY SYSTEM AND USES THEREOF | April 2020 | November 2022 | Abandon | 31 | 2 | 0 | No | No |
| 16758951 | POWDER COSMETIC COMPOSITION CONTAINING STARCH | April 2020 | January 2023 | Abandon | 33 | 2 | 0 | Yes | No |
| 16757290 | TRANSDERMAL DELIVERY SYSTEM CONTAINING A DOPAMINE AGONIST | April 2020 | November 2022 | Abandon | 30 | 0 | 1 | No | No |
| 16756366 | COMPOSITION AND DEVICE FOR DELIVERY OF ACTIVE AGENTS TO SKIN SURFACES | April 2020 | May 2023 | Abandon | 37 | 2 | 1 | No | No |
| 16837621 | SOLID COSMETIC COMPOSITION FOR EYE MAKE-UP INCLUDING FIBER | April 2020 | October 2023 | Abandon | 43 | 4 | 0 | Yes | No |
| 16833209 | INHIBITING VIRAL AND BACTERIAL ACTIVITY USING LOW CONCENTRATION HYPOCHLOROUS ACID SOLUTIONS | March 2020 | September 2022 | Abandon | 30 | 6 | 0 | Yes | No |
| 16650961 | Glucocorticoid "Nintedanib" Particles and Their Use | March 2020 | November 2023 | Allow | 44 | 3 | 1 | Yes | No |
| 16827629 | GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS | March 2020 | October 2023 | Abandon | 43 | 2 | 1 | Yes | Yes |
| 16820692 | MULTIPURPOSE IMPLANT WITH MODELED SURFACE STRUCTURE | March 2020 | November 2022 | Abandon | 32 | 2 | 0 | Yes | No |
| 16808117 | Laundry Additive for Providing Antimicrobial Effects to Fabrics and Interior Surfaces of Washing Machines | March 2020 | September 2021 | Abandon | 18 | 1 | 1 | Yes | No |
| 16803532 | DERMAL DEVICE FOR ADMINISTRATION OF ONE OR MORE ACTIVE AGENTS TO THE SKIN | February 2020 | May 2022 | Abandon | 26 | 0 | 1 | No | No |
| 16641741 | TRANSDERMAL DELIVERY SYSTEM INCLUDING AN EMULSIFIER | February 2020 | March 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 16799578 | BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY | February 2020 | June 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16795497 | THIOL AND DISULFIDE-CONTAINING AGENTS FOR INCREASING MEIBOMIAN GLAND LIPID SECRETION | February 2020 | February 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16639810 | MICROPARTICLES CONTAINING FINASTERIDE AND PREPARATION METHOD THEREOF | February 2020 | April 2022 | Allow | 26 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GHALI, ISIS A D.
With a 26.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GHALI, ISIS A D works in Art Unit 1611 and has examined 877 patent applications in our dataset. With an allowance rate of 25.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner GHALI, ISIS A D's allowance rate of 25.7% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GHALI, ISIS A D receive 3.31 office actions before reaching final disposition. This places the examiner in the 98% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by GHALI, ISIS A D is 43 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +38.4% benefit to allowance rate for applications examined by GHALI, ISIS A D. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 5.2% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 18.4% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 52.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 44% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 52.3% of appeals filed. This is in the 18% percentile among all examiners. Of these withdrawals, 36.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 53.7% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.4% of allowed cases (in the 79% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.